Sun Pharmaceutical Industries Ltd. has entered into exclusive licensing and supply agreements with Rockwell Medical Inc., to commercialize Rockwell’s Triferic, a proprietary iron-replacement and hemoglobin-maintenance drug, for treating anemia in hemodialysis patients in India. Triferic is approved in the USA. As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialization partner for Triferic during the term of the agreement, subject to its approval in India. In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as royalty on net sales. The financial terms of the agreement are confidential.